The company along with its subsidiaries has overall bed capacity of 8800+ beds as on 30th September, 2025
Healthcare and insurance are not parallel systems; they are interdependent pillars of patient trust
GSK will make most of its inhaled respiratory portfolio and other products available on a direct purchasing platform, offering savings of up to 66%
The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the facility
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
The EIR was issued following an inspection of the facility from September 8 to September 16, 2025
Bertozzi currently serves as the Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor at Stanford University, and Investigator of the Howard Hughes Medical Institute
The company shall process the change of name application with BSE Ltd. in due course
Subscribe To Our Newsletter & Stay Updated
